Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234663 | 0.93 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234639 | 0.93 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2545185 | 0.92 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234638 | 0.92 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234641 | 0.90 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234636 | 0.89 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2542473 | 0.89 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2542471 | 0.89 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234653 | 0.87 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12234656 | 0.87 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| US-10370332-B2 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof | MACROPHAGE PHARMA LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20180127371-A1 | TERT-BUTYL N-[2-{4-[6-AMINO-5-(2,4-DIFLUOROBENZOYL)-2-OXOPYRIDIN-1(2H)-YL]-3,5- DIFLUOROPHENYL}ETHYL]-L-ALANINATE OR A SALT,HYDRATE OR SOLVATE THEREOF | MACROPHAGE PHARMA LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9388136-B2 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof | CHROMA THERAPEUTICS LTD (GB) | 2016-07-12 | — | — | US | disclosed |
| US-20150246883-A1 | TERT-BUTYL N-[2-ETHYL]-L-ALANINATE OR A SALT, HYDRATE OR SOLVATE THEREOF | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-03 | — | — | US | disclosed |
| WO-2014060742-A1 | TERT-BUTYL N-[2-{4-[6-AMINO-5-(2,4-DIFLUOROBENZOYL)-2-OXOPYRIDIN-1(2H)-YL]-3,5- DIFLUOROPHENYL}ETHYL]-L-ALANINATE OR A SALT, HYDRATE OR SOLVATE THEREOF | CHROMA THERAPEUTICS LTD (GB) | 2014-04-24 | — | — | WO | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246883-A1 | TERT-BUTYL N-[2-ETHYL]-L-ALANINATE OR A SALT, HYDRATE OR SOLVATE THEREOF | MAPK1, MAPK6, MAPK15 | MAPK14 7/4885MAPK13 10/4885MAPK12 20/4885 |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | MAPK14 15/4885MAPK13 6/4885MAPK12 5/4885 |
| US-20180127371-A1 | TERT-BUTYL N-[2-{4-[6-AMINO-5-(2,4-DIFLUOROBENZOYL)-2-OXOPYRIDIN-1(2H)-YL]-3,5- DIFLUOROPHENYL}ETHYL]-L-ALANINATE OR A SALT,HYDRATE OR SOLVATE THEREOF | MAPK1, MAPK6, MAPK15 | MAPK14 11/4885MAPK13 18/4885MAPK12 14/4885 |
| US-10370332-B2 | Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-YL]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof | MAPK1, MAPK6, MAPK15 | MAPK14 11/4885MAPK13 18/4885MAPK12 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.